ZA202203520B - [1,4]oxazepino[2,3-c]quinolinone derivatives as bcl6 inhibitors - Google Patents
[1,4]oxazepino[2,3-c]quinolinone derivatives as bcl6 inhibitorsInfo
- Publication number
- ZA202203520B ZA202203520B ZA2022/03520A ZA202203520A ZA202203520B ZA 202203520 B ZA202203520 B ZA 202203520B ZA 2022/03520 A ZA2022/03520 A ZA 2022/03520A ZA 202203520 A ZA202203520 A ZA 202203520A ZA 202203520 B ZA202203520 B ZA 202203520B
- Authority
- ZA
- South Africa
- Prior art keywords
- oxazepino
- bcl6
- quinolinone derivatives
- inhibitors
- bcl6 inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201914860A GB201914860D0 (en) | 2019-10-14 | 2019-10-14 | Inhibitor compounds |
| PCT/GB2020/052588 WO2021074620A1 (en) | 2019-10-14 | 2020-10-14 | [1,4]oxazepino[2,3-c]qui noli none derivatives as blc6 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202203520B true ZA202203520B (en) | 2025-09-25 |
Family
ID=68619494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2022/03520A ZA202203520B (en) | 2019-10-14 | 2022-03-25 | [1,4]oxazepino[2,3-c]quinolinone derivatives as bcl6 inhibitors |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12528826B2 (enExample) |
| EP (1) | EP4045510B1 (enExample) |
| JP (1) | JP7668273B2 (enExample) |
| KR (1) | KR20220083761A (enExample) |
| CN (1) | CN114650995A (enExample) |
| AU (1) | AU2020365518B2 (enExample) |
| CA (1) | CA3157716A1 (enExample) |
| ES (1) | ES3047908T3 (enExample) |
| GB (1) | GB201914860D0 (enExample) |
| IL (1) | IL292182B2 (enExample) |
| MX (1) | MX2022004419A (enExample) |
| WO (1) | WO2021074620A1 (enExample) |
| ZA (1) | ZA202203520B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL296734B2 (en) | 2018-04-13 | 2025-06-01 | The Institute Of Cancer Res Royal Cancer Hospital | Bcl6 inhibitors |
| GB201914860D0 (en) | 2019-10-14 | 2019-11-27 | Cancer Research Tech Ltd | Inhibitor compounds |
| MX2022004526A (es) | 2019-10-17 | 2022-07-21 | Arvinas Operations Inc | Moléculas bifuncionales que contienen una porción de unión a la ligasa de ubiquitina e3 unida a una porción de direccionamiento a bcl6. |
| CN118388454A (zh) | 2021-04-16 | 2024-07-26 | 阿尔维纳斯运营股份有限公司 | Bcl6蛋白水解的调节剂和其相关使用方法 |
| WO2023240038A1 (en) * | 2022-06-06 | 2023-12-14 | Treeline Biosciences, Inc. | Tricyclic quinolone bcl6 bifunctional degraders |
| AU2023295387A1 (en) | 2022-06-13 | 2025-01-09 | Treeline Biosciences, Inc. | 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders |
| KR20250023483A (ko) | 2022-06-13 | 2025-02-18 | 트리라인 바이오사이언시스, 인크. | 퀴놀론 bcl6 이작용성 분해제 |
| WO2024228505A1 (ko) * | 2023-05-03 | 2024-11-07 | 인제대학교 산학협력단 | Btk 분해제 및 bcl-6 분해제를 포함하는 암의 예방 또는 치료용 약학적 조성물 |
| TW202525814A (zh) * | 2023-09-01 | 2025-07-01 | 美商樹線生物科學公司 | 三環喹啉酮ｂｃｌ６雙功能降解劑 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0259572A (ja) | 1988-08-23 | 1990-02-28 | Mitsubishi Kasei Corp | ベンズイミダゾロン誘導体又はその塩類 |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| CA2242425C (en) | 1996-02-13 | 2006-07-18 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| EP1144387A1 (en) | 1998-12-04 | 2001-10-17 | Neurosearch A/S | New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| EE05345B1 (et) | 1999-02-10 | 2010-10-15 | Astrazeneca Ab | Kinasoliini derivaadid angiogeneesi inhibiitoritena |
| TR200200161T2 (tr) | 1999-07-21 | 2002-05-21 | Fujisawa Pharmaceutical Co. Ltd. | Benzimidazol türevleri ve onların fosfodiesteraz olarak kullanımı. |
| BR0111230A (pt) | 2000-05-31 | 2003-06-10 | Astrazeneca Ab | Composto, e, uso e processo para a preparação do mesmo |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| WO2001094311A1 (en) | 2000-06-08 | 2001-12-13 | Mitsubishi Pharma Corporation | Cytoprotectors |
| EE200300015A (et) | 2000-07-07 | 2004-10-15 | Angiogene Pharmaceuticals Limited | Kolhinooli derivaadid kui angiogeneesi inhibiitorid |
| KR20030014425A (ko) | 2000-07-07 | 2003-02-17 | 앤지오젠 파마슈티칼스 리미티드 | 혈관 손상제인 콜치놀 유도체 |
| UY27304A1 (es) | 2001-05-24 | 2002-12-31 | Avanir Pharmaceuticals | Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación |
| WO2003095448A1 (en) | 2002-05-06 | 2003-11-20 | Bayer Pharmaceuticals Corporation | Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders |
| US7825132B2 (en) | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
| US20050256157A1 (en) | 2002-08-23 | 2005-11-17 | Chiron Corporation | Combination therapy with CHK1 inhibitors |
| CA2656507C (en) | 2006-07-17 | 2012-03-20 | Amgen Inc. | Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors |
| WO2008066887A2 (en) | 2006-11-30 | 2008-06-05 | Albert Einstein College Of Medicine Of Yeshiva University | Small molecule inhibitors of bcl6 |
| US8686008B2 (en) | 2007-08-16 | 2014-04-01 | The University Of Mississippi | Highly selective sigma receptor ligands |
| WO2009063240A1 (en) | 2007-11-16 | 2009-05-22 | Arrow Therapeutics Limited | 2,4-diaminopyrimidine derivatives useful as inhibitors of aurora kinase |
| WO2009097578A1 (en) | 2008-02-01 | 2009-08-06 | Takeda Pharmaceutical Company Limited | Oxim derivatives as hsp90 inhibitors |
| PL2364983T3 (pl) | 2008-11-11 | 2014-04-30 | Jeil Pharmaceutical Co Ltd | Nowa pochodna tricykliczna lub jej farmaceutycznie dopuszczalne sole, sposób jej wytwarzania, oraz zawierająca ją kompozycja farmaceutyczna |
| PL2389372T3 (pl) | 2009-01-23 | 2016-02-29 | Rigel Pharmaceuticals Inc | Kompozycje i sposoby hamowania szlaku JAK |
| CN102791131A (zh) | 2010-01-13 | 2012-11-21 | 葛兰素史密斯克莱有限责任公司 | 化合物和方法 |
| ES2698847T3 (es) | 2011-07-07 | 2019-02-06 | Merck Patent Gmbh | Azaheterociclos sustituidos para el tratamiento del cáncer |
| US9499562B2 (en) | 2012-06-18 | 2016-11-22 | Dart Neuroscience (Cayman) Ltd. | Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds |
| CN105143215B (zh) | 2013-03-05 | 2017-12-08 | 豪夫迈·罗氏有限公司 | 布鲁顿氏酪氨酸激酶抑制剂 |
| US9943506B2 (en) | 2013-06-17 | 2018-04-17 | Cornell University | BCL6 inhibitors as anticancer agents |
| CN105017159B (zh) | 2014-04-28 | 2019-05-17 | 四川大学 | 5-氟-2,4-二取代氨基嘧啶衍生物及其制备方法和用途 |
| ES2914099T3 (es) | 2014-08-25 | 2022-06-07 | Salk Inst For Biological Studi | Inhibidores novedosos de ULK1 y métodos de uso de los mismos |
| US20160060260A1 (en) | 2014-08-29 | 2016-03-03 | Board Of Regents, The University Of Texas System | Bromodomain inhibitors for treating disease |
| WO2016090382A1 (en) | 2014-12-06 | 2016-06-09 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2017007658A1 (en) | 2015-07-07 | 2017-01-12 | Rigel Pharmaceuticals, Inc. | A combination for immune mediated cancer treatment |
| JP6999688B2 (ja) * | 2016-12-13 | 2022-02-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｂｃｌ６阻害剤としての新規の６－アミノキノリノン化合物および誘導体 |
| EP3630749B9 (en) | 2017-05-26 | 2024-05-29 | Cancer Research Technology Limited | 2-quinolone derived inhibitors of bcl6 |
| EP3630291B9 (en) | 2017-05-26 | 2024-05-29 | Cancer Research Technology Limited | Benzimidazolone derived inhibitors of bcl6 |
| IL296734B2 (en) * | 2018-04-13 | 2025-06-01 | The Institute Of Cancer Res Royal Cancer Hospital | Bcl6 inhibitors |
| GB201819136D0 (en) | 2018-11-23 | 2019-01-09 | Cancer Research Tech Ltd | Inhibitor compounds |
| GB201914860D0 (en) | 2019-10-14 | 2019-11-27 | Cancer Research Tech Ltd | Inhibitor compounds |
-
2019
- 2019-10-14 GB GB201914860A patent/GB201914860D0/en not_active Ceased
-
2020
- 2020-10-13 IL IL292182A patent/IL292182B2/en unknown
- 2020-10-14 KR KR1020227016037A patent/KR20220083761A/ko active Pending
- 2020-10-14 CA CA3157716A patent/CA3157716A1/en active Pending
- 2020-10-14 WO PCT/GB2020/052588 patent/WO2021074620A1/en not_active Ceased
- 2020-10-14 ES ES20793780T patent/ES3047908T3/es active Active
- 2020-10-14 MX MX2022004419A patent/MX2022004419A/es unknown
- 2020-10-14 CN CN202080072281.5A patent/CN114650995A/zh active Pending
- 2020-10-14 US US17/768,174 patent/US12528826B2/en active Active
- 2020-10-14 AU AU2020365518A patent/AU2020365518B2/en active Active
- 2020-10-14 EP EP20793780.6A patent/EP4045510B1/en active Active
- 2020-10-14 JP JP2022522065A patent/JP7668273B2/ja active Active
-
2022
- 2022-03-25 ZA ZA2022/03520A patent/ZA202203520B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022551950A (ja) | 2022-12-14 |
| CA3157716A1 (en) | 2021-04-22 |
| AU2020365518A1 (en) | 2022-04-14 |
| US20240217987A1 (en) | 2024-07-04 |
| JP7668273B2 (ja) | 2025-04-24 |
| AU2020365518B2 (en) | 2026-04-23 |
| GB201914860D0 (en) | 2019-11-27 |
| EP4045510A1 (en) | 2022-08-24 |
| KR20220083761A (ko) | 2022-06-20 |
| ES3047908T3 (en) | 2025-12-05 |
| EP4045510B1 (en) | 2025-07-30 |
| IL292182B2 (en) | 2026-06-01 |
| MX2022004419A (es) | 2022-08-08 |
| IL292182A (en) | 2022-06-01 |
| WO2021074620A1 (en) | 2021-04-22 |
| WO2021074620A9 (en) | 2021-06-17 |
| IL292182B1 (en) | 2026-02-01 |
| US12528826B2 (en) | 2026-01-20 |
| CN114650995A (zh) | 2022-06-21 |
| EP4045510C0 (en) | 2025-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022004419A (es) | Derivados de [1,4]oxazepino[2,3c]quinolinona como inhibidores de bcl6. | |
| MX2023005636A (es) | Inhibidores de bcl6 derivados de bencimidazolona. | |
| EP4371562A3 (en) | 2-quinolone derived inhibitors of bcl6 | |
| MX2020010805A (es) | Inhibidores de bcl6. | |
| PH12022552739A1 (en) | Fused tricyclic kras inhibitors | |
| GEAP202416515A (en) | Quinoline compounds as inhibitors of kras | |
| MX2022013223A (es) | [1,3]diazino[5,4-d]pirimidinas como inhibidores de her2. | |
| MX2022015739A (es) | Inhibidores alostericos de egfr y metodos de uso de estos. | |
| GEAP202616866A (en) | 2-azabicyclo[2.2.1]heptane kras inhibitors | |
| CR20240059A (es) | Compuestos tricíclicos como inhibidores de kras. | |
| MX2021013110A (es) | Compuestos heterociclicos como inhibidores de la cinasa ret. | |
| MX2023012981A (es) | Compuestos para inhibir o degradar proteinas objetivo, composiciones que los comprenden, metodos para su preparacion y metodos para usarlos. | |
| EP4420728A3 (en) | Novel chroman derivatives having estrogen receptor degradation activity and uses thereof | |
| CR20210544A (es) | DERIVADOS DE 1,1-DIÓXIDO DE 3-AMINO-4H-BENZO[E][1,2,4] tiadiazina COMO INHIBIDORES DE MRGX2 | |
| PH12022550015A1 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| EP3722296A3 (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
| PH12022550843A1 (en) | Thienopyrimidones as trpa1 inhibitors | |
| GEP20227442B (en) | Boron containing pde4 inhibitors | |
| MX2021008667A (es) | Derivado de pirrolopirimidina y composición farmacéutica para prevenir o tratar enfermedades relacionadas con la proteína quinasa que comprende el mismo como principio activo. | |
| MX2022000390A (es) | Derivados macrociclicos espirociclicos como inhibidores de mcl-1. | |
| MX2020010568A (es) | Derivados de urea ciclica fusionada como antagonista de crhr2. | |
| JOP20220107A1 (ar) | مثبطات egfr تفارغية وطرق استخدامها | |
| PH12019501642A1 (en) | Novel compounds and their use in the treatment of schistosomiasis | |
| MX2024004874A (es) | Compuestos heterociclicos para uso en el tratamiento de cancer. | |
| PH12022550846A1 (en) | Thienopyrimidones as trpa1 inhibitors |